Plasma GFAP associates with secondary Alzheimer's pathology in Lewy body disease
Annals of Clinical and Translational Neurology · 2023-05 · 10 (5) · 802-813
DOI: 10.1002/acn3.51768 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, online erschienen am 31.03.2023. Verfasst von Katheryn A Q Cousins und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Perelman School of Medicine, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Lewy Body Disease, Alzheimer Disease. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, NIA NIH HHS, Alzheimer's Association.
Themen: Demenz
Abstract (Originalsprache)
Objective
Within Lewy body spectrum disorders (LBSD) with α‐synuclein pathology (αSyn), concomitant Alzheimer's disease (AD) pathology is common and is predictive of clinical outcomes, including cognitive impairment and decline. Plasma phosphorylated tau 181 (p‐tau 181 ) is sensitive to AD neuropathologic change (ADNC) in clinical AD, and plasma glial fibrillary acidic protein (GFAP) is associated with the presence of β‐amyloid plaques. While these plasma biomarkers are well tested in clinical and pathological AD, their diagnostic and prognostic performance for concomitant AD in LBSD is unknown.
Methods
In autopsy‐confirmed αSyn‐positive LBSD, we tested how plasma p‐tau 181 and GFAP differed across αSyn with concomitant ADNC (αSyn+AD; n = 19) and αSyn without AD (αSyn; n = 30). Severity of burden was scored on a semiquantitative scale for several pathologies (e.g., β‐amyloid and tau), and scores were averaged across sampled brainstem, limbic, and neocortical regions.
Results
Linear models showed that plasma GFAP was significantly higher in αSyn+AD compared to αSyn ( β = 0.31, 95% CI = 0.065–0.56, and P = 0.015), after covarying for age at plasma, plasma‐to‐death interval, and sex; plasma p‐tau 181 was not ( P = 0.37). Next, linear models tested associations of AD pathological features with both plasma analytes, covarying for plasma‐to‐death, age at plasma, and sex. GFAP was significantly associated with brain β ‐amyloid ( β = 15, 95% CI = 6.1–25, and P = 0.0018) and tau burden ( β = 12, 95% CI = 2.5–22, and P = 0.015); plasma p‐tau 181 was not associated with either (both P > 0.34).
Interpretation
Findings indicate that plasma GFAP may be sensitive to concomitant AD pathology in LBSD, especially accumulation of β‐amyloid plaques.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
- Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
ORCID-Profile: Katheryn A Q Cousins, David J Irwin, Sanaz Arezoumandan, Daniel Weintraub
Förderung
- NINDS NIH HHS
- NIA NIH HHS
- Alzheimer's Association
- National Institute of Neurological Disorders and Stroke
- National Institute on Aging
Zitieren
APA
Cousins, K. A. Q., Irwin, D. J., Chen-Plotkin, A., Shaw, L. M., Arezoumandan, S., Lee, E. B., Wolk, D. A., Weintraub, D., Spindler, M., Deik, A., Grossman, M., & Tropea, T. F. (2023). Plasma GFAP associates with secondary Alzheimer's pathology in Lewy body disease. Annals of Clinical and Translational Neurology, 10(5), 802-813. https://doi.org/10.1002/acn3.51768
Vancouver
Cousins KAQ, Irwin DJ, Chen-Plotkin A, Shaw LM, Arezoumandan S, Lee EB, et al. Plasma GFAP associates with secondary Alzheimer's pathology in Lewy body disease. Annals of Clinical and Translational Neurology. 2023;10(5):802-813. doi:10.1002/acn3.51768
BibTeX
@article{Cousins2023,
author = {Cousins, Katheryn A Q and Irwin, David J and Chen-Plotkin, Alice and Shaw, Leslie M and Arezoumandan, Sanaz and Lee, Edward B and Wolk, David A and Weintraub, Daniel and Spindler, Meredith and Deik, Andres and Grossman, Murray and Tropea, Thomas F},
title = {Plasma GFAP associates with secondary Alzheimer's pathology in Lewy body disease},
journal = {Annals of Clinical and Translational Neurology},
year = {2023},
volume = {10},
number = {5},
pages = {802--813},
doi = {10.1002/acn3.51768}
}
EUVIMED